CAPS Medical

CAPS Medical Overview

CAPS Medical is a medical device company focused on the development and commercialization of its NTAP System, which uses non-thermal atmospheric plasma (NTAP) to treat a wide range of solid tumors. The minimally invasive and selective cancer treatment targets solid tumors and aims to selectively and precisely destroy only cancerous cells, leaving healthy tissue intact. The company has obtained outstanding results from its first clinical study focusing on non-muscle invasive bladder cancer (NMIBC), the sixth most common cancer . Worldwide, more than 1.6 M people suffer from NMIBC, with around 200,000 new cases annually. In addition the company has demonstrated feasibility to enable the technology’s use for additional cancers including in lungs, esophagus, stomach ,GI and others. Originally developed at the Technion - Israel Institute of Technology, the system is supported by key opinion leaders from medical fields such as oncology and interventional radiology. CAPS Medical has been supported by major shareholders and a strategic investo.

Cumulative Funding Raised Over Time ($)

Latest News

Oct 15, 2025 · www.prnewswire.com

growth-positive

/PRNewswire/ -- CAPS Medical, a clinical-stage MedTech company developing a platform for selective tumor ablation across multiple indications, today announced...

CAPS Medical, a clinical-stage MedTech company, has received Breakthrough Device Designation from the FDA for its PlasmaSure™ System, aimed at treating non-muscle invasive bladder cancer (NMIBC). This designation supports the companys mission to transform tumor ablation into a simple, in-office procedure. The PlasmaSure™ platform uses non-thermal atmospheric plasma energy for selective tumor ablation, preserving healthy tissue. CAPS Medical has completed a first-in-human clinical study with promising results and is preparing for pivotal trials and U.S. market entry. The company is also expanding its technology to other cancer indications and establishing a U.S. headquarters to support its growth phase.

Product StageFDA approved/pending approvalExpand

Jul 18, 2021 · forbes.co.il

"בדרך למהפך בטיפול בגידולים סרטניים" - Forbes Israel

Jul 18, 2021 · www.globes.co.il

growth-positive

CAPS Medical גייסה 3.5 מיליון דולר לניסוי הקליני הראשון שלה

CAPS Medical, a company developing a new method for cancer growth removal, has raised $3.5 million for its first clinical trial. The company was founded within the MEDX Xelerator incubator, established by medical device entrepreneur Harel Gadot. The investors in this round were Chasing Value Asset Management, Israel Investment Fund Group, XACT Robotics, and the Technions venture capital fund. CAPS uses cold plasma to treat cancer, a technology that has shown promise in selectively killing cancer cells. The companys system minimizes the exposure of healthy cells to plasma, allowing for more targeted and selective treatment with fewer side effects. CAPS was developed in collaboration with the Technion and Rambam Hospital.

Investment

Jul 29, 2020 · www.prnewswire.com

growth-positive

CAPS Medical Completes $3.5 Million Series A Round for Selective Cancer Treatment Technology

CAPS Medical, a developer of a non-thermal plasma device for cancer treatment, has announced the completion of a $3.5 million Series A financing round. The funding will support the companys first clinical trial and further development of its portfolio for treating solid tumors. CAPS Medical aims to achieve regulatory clearance in the U.S. market based on the results of these studies. The financing round was led by Chasing Value Asset Management and the Israel Investment Fund Group, with participation from other investors including the Technion Research and Development Foundation and XACT Robotics. The companys platform uses non-thermal plasma to selectively target and kill cancer cells without damaging healthy tissue, offering a more precise and less harmful treatment option.

Investment

Jul 12, 2020 · www.israel21c.org

growth-positive

New plasma cancer treatment kills malignant cells

CAPS Medical, a small startup based in Or Yehuda, Israel, has developed a disposable catheter that delivers cold atmospheric plasma (CAP) to treat non-muscle invasive bladder cancer (NMIBC). CAPS Medicals technology allows CAP to reach deep into the body, causing cancer cell death and triggering an immune response that targets additional cancer cells. The company plans to expand its technology to other types of solid organ tumors. CAPS Medical is currently in the prototype stage and aims to develop a clinical-grade system for testing on humans. The company has received support from the MEDX technology accelerator and has won awards for its innovation. It is backed by investors such as Boston Scientific, Intellectual Ventures, MEDX Ventures, and Sheba Medical Center.

Customers

Funding

Team Members

1

Employees: 11-50

Web & Social Links

Locations

Ha-Melakha St, Netanya, Israel

Photos & Videos

1 item(s)

CAPS Medical Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info